Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Ron Sigourney who wrote (6130)	1/12/1999 3:53:00 PM
From: Dauntless	Read Replies (3) \| Respond to of 7041

Ron & Thread - '99 EARNINGS EST. INCREASED - OPPENHEIMER This was posted on the Yahoo board this afternoon... ....some highlights from a CIBC Oppenheimer report just released yesterday. It was based on a conference call that Zona management held with analysts to discuss 1999. Highlights - CIBC/Opp raises its 1999 EPS estimates to positive $0.93 (yes, almost a buck) from minus $0.58 based upon higher royalty revenues, milestone payments and lower expenditures (resulting from the expectation that Schering will take on full rsponsibility for manufacturing). - 2000 eps revised to $0.74 (from $0.09), 2001 revised to $1.33 (from $1.00), 2002 revised to $4.05 (from $3.62) - UK approval is expected in 2Q99. To ensure uniform labeling, Schering will most likely launch Vasomax globally in second half of year after approval in US, UK and Europe. ZONA expected to recognize royalties one quarter after distribution of product. - To quote report, "Given the large potential market...and, in our opinion, its lack of any cardiovascular side effects, we view Vasomax as one of the most exciting new product stories and launches to come out of the sector in 1999." - Zona is not a one product company. Vasofem is cited as first of its kind to go into human clinical trials. Also, Zona is investigating second generation "oral combination therapy for MSD (Bimexes) and an injectable agent for severe erectile dysfunction that is refractory to oral medication (Erxin) and a prostate antigen therapeutic vaccine (Zproxal)." - - Big share increase last week was attributable to favorable article in UK periodical.